About NEDD4-binding protein 3
NEDD4-binding protein 3 (N4BP3) is a protein
from Homo sapiens identified by UniProt accession
O15049, 544 residues long.
MolForge cross-references it against 0 known binders and
10 disease associations.
Target properties
| Protein name | NEDD4-binding protein 3 |
| UniProt accession | O15049 |
| Gene | N4BP3 |
| Organism | Homo sapiens |
| Length | 544 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (10)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.38
- hepatocellular carcinoma · score 0.08
- neoplasm · score 0.07
- esophageal squamous cell carcinoma · score 0.03
- prostate carcinoma · score 0.01
- visceral Leishmaniasis · score 0.00
- brucellosis · score 0.00
- metastatic melanoma · score 0.00
- Crohn's disease · score 0.00
- type 2 diabetes mellitus · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O15049-F1 | alphafold | PREDICTED | 64.11 | — |
Amino-acid sequence (544 residues)
MATAPGPAGI AMGSVGSLLE RQDFSPEELR AALAGSRGSR QPDGLLRKGL GQREFLSYLH LPKKDSKSTK NTKRAPRNEP ADYATLYYRE HSRAGDFSKT SLPERGRFDK CRIRPSVFKP TAGNGKGFLS MQSLASHKGQ KLWRSNGSLH TLACHPPLSP GPRASQARAQ LLHALSLDEG GPEPEPSLSD SSSGGSFGRS PGTGPSPFSS SLGHLNHLGG SLDRASQGPK EAGPPAVLSC LPEPPPPYEF SCSSAEEMGA VLPETCEELK RGLGDEDGSN PFTQVLEERQ RLWLAELKRL YVERLHEVTQ KAERSERNLQ LQLFMAQQEQ RRLRKELRAQ QGLAPEPRAP GTLPEADPSA RPEEEARWEV CQKTAEISLL KQQLREAQAE LAQKLAEIFS LKTQLRGSRA QAQAQDAELV RLREAVRSLQ EQAPREEAPG SCETDDCKSR GLLGEAGGSE ARDSAEQLRA ELLQERLRGQ EQALRFEQER RTWQEEKERV LRYQREIQGG YMDMYRRNQA LEQELRALRE PPTPWSPRLE SSKI
Explore NEDD4-binding protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets